Contact
searchSearch
HMP Global
Login

Chronic Myeloid Leukemia Specialty Channel

Chronic Myeloid Leukemia
Specialty Channel
FDA Approval
FDA Grants Accelerated Approval to Frontline Asciminib for Patients With Ph+ Chronic Myeloid Leukemia
10/29/2024
The FDA granted accelerated approval to asciminib for patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
The FDA granted accelerated approval to asciminib for patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
The FDA granted accelerated...
10/29/2024
Oncology
News
Nilotinib, Dasatinib, or Flumatinib vs Imatinib as Frontline Therapy for Patients With Chronic-Phase Chronic Myeloid Leukemia
03/22/2024

Amber Denham

Amber Denham
According to a real-world, retrospective study, nilotinib, dasatinib, or flumatinib therapy each showed comparable efficacy, higher therapy responses and higher failure-free survival rates than imatinib among newly diagnosed patients with...
According to a real-world, retrospective study, nilotinib, dasatinib, or flumatinib therapy each showed comparable efficacy, higher therapy responses and higher failure-free survival rates than imatinib among newly diagnosed patients with...
According to a real-world,...
03/22/2024
Oncology
News
Asciminib Demonstrated Superior Efficacy and Safety Compared to Bosutinib Among Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
06/23/2023
Results from the ASCEMBL trial indicated that asciminib, a BCR::ABL1 inhibitor, demonstrated superior efficacy and safety compared to bosutinib among patients with Philadelphia chromosome-positive chronic myeloid leukemia.
Results from the ASCEMBL trial indicated that asciminib, a BCR::ABL1 inhibitor, demonstrated superior efficacy and safety compared to bosutinib among patients with Philadelphia chromosome-positive chronic myeloid leukemia.
Results from the ASCEMBL trial...
06/23/2023
Oncology
News
Olverembatinib Well-Tolerated in Adults With TKI-Resistant Chronic Myeloid Leukemia
10/17/2022
Olverembatinib, a novel tyrosine kinase inhibitor (TKI), was well tolerated and demonstrated significant anti-leukemic activity in adults with TKI-resistant CML-CP and CML-AP, especially those with the T315I mutation, according to results...
Olverembatinib, a novel tyrosine kinase inhibitor (TKI), was well tolerated and demonstrated significant anti-leukemic activity in adults with TKI-resistant CML-CP and CML-AP, especially those with the T315I mutation, according to results...
Olverembatinib, a novel tyrosine...
10/17/2022
Oncology
News
FDA Approves Asciminib for Ph+ CML
11/01/2021
The FDA granted accelerated approval to asciminib for the use in the treatment of patients with Ph+ CML in CP with or without the T315I mutation who were previously treated with 2 or more TKIs.
The FDA granted accelerated approval to asciminib for the use in the treatment of patients with Ph+ CML in CP with or without the T315I mutation who were previously treated with 2 or more TKIs.
The FDA granted accelerated...
11/01/2021
Oncology
Test Your Knowledge
Quiz: Which of the Following is Not a Standard of Care Treatment Option for CML?
09/10/2021
Which of the following is not a current standard of care option for the treatment of patients with CML?
Which of the following is not a current standard of care option for the treatment of patients with CML?
Which of the following is not a...
09/10/2021
Oncology
Test Your Knowledge
Quiz: Is the Major BCR-ABL1 Transcript Type Linked to Better Imatinib Response in CML?
04/20/2021
Study findings reported by researchers in Algeria suggest that b3a2 transcript may be tied to ____ (better/worse) responses to imatinib therapy in patients with chronic myeloid leukemia.
Study findings reported by researchers in Algeria suggest that b3a2 transcript may be tied to ____ (better/worse) responses to imatinib therapy in patients with chronic myeloid leukemia.
Study findings reported by...
04/20/2021
Oncology
Test Your Knowledge
Quiz: Which Treatment is Considered Gold Standard for CML-CP?
03/16/2021
According to experts, which of the following therapy options is considered the gold standard for frontline treatment of newly diagnosed chronic myeloid leukemia in chronic-phase?
According to experts, which of the following therapy options is considered the gold standard for frontline treatment of newly diagnosed chronic myeloid leukemia in chronic-phase?
According to experts, which of...
03/16/2021
Oncology
Test Your Knowledge
Quiz: Have TKIs Improved the CML Alternative Treatment Landscape?
02/17/2021
Prior to experts utilizing tyrosine kinase inhibitors as treatment for chronic myeloid leukemia, a stem cell transplant was required.
Prior to experts utilizing tyrosine kinase inhibitors as treatment for chronic myeloid leukemia, a stem cell transplant was required.
Prior to experts utilizing...
02/17/2021
Oncology
Test Your Knowledge
Quiz: What Was the Outcome of the ASCEMBL Trial?
12/23/2020
True of False: The ASCEMBL data concludes that, with ABL-specific inhibition, asciminib has a reduced rate of side effects that lead to discontinuation or dose adjustment compared to the TKI drug bosutinib, while improving the response rate...
True of False: The ASCEMBL data concludes that, with ABL-specific inhibition, asciminib has a reduced rate of side effects that lead to discontinuation or dose adjustment compared to the TKI drug bosutinib, while improving the response rate...
True of False: The ASCEMBL data...
12/23/2020
Oncology
Test Your Knowledge
Quiz: Is Imatinib Considered Gold Standard Frontline Treatment for CML-CP?
11/25/2020
True or False: Imatinib is considered the gold standard for frontline treatment of newly diagnosed chronic myeloid leukemia in chronic-phase.
True or False: Imatinib is considered the gold standard for frontline treatment of newly diagnosed chronic myeloid leukemia in chronic-phase.
True or False: Imatinib is...
11/25/2020
Oncology

News

FDA Approval
FDA Grants Accelerated Approval to Frontline Asciminib for Patients With Ph+ Chronic Myeloid Leukemia
10/29/2024
The FDA granted accelerated approval to asciminib for patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
The FDA granted accelerated approval to asciminib for patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
The FDA granted accelerated...
10/29/2024
Oncology
News
Nilotinib, Dasatinib, or Flumatinib vs Imatinib as Frontline Therapy for Patients With Chronic-Phase Chronic Myeloid Leukemia
03/22/2024

Amber Denham

Amber Denham
According to a real-world, retrospective study, nilotinib, dasatinib, or flumatinib therapy each showed comparable efficacy, higher therapy responses and higher failure-free survival rates than imatinib among newly diagnosed patients with...
According to a real-world, retrospective study, nilotinib, dasatinib, or flumatinib therapy each showed comparable efficacy, higher therapy responses and higher failure-free survival rates than imatinib among newly diagnosed patients with...
According to a real-world,...
03/22/2024
Oncology
News
Asciminib Demonstrated Superior Efficacy and Safety Compared to Bosutinib Among Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
06/23/2023
Results from the ASCEMBL trial indicated that asciminib, a BCR::ABL1 inhibitor, demonstrated superior efficacy and safety compared to bosutinib among patients with Philadelphia chromosome-positive chronic myeloid leukemia.
Results from the ASCEMBL trial indicated that asciminib, a BCR::ABL1 inhibitor, demonstrated superior efficacy and safety compared to bosutinib among patients with Philadelphia chromosome-positive chronic myeloid leukemia.
Results from the ASCEMBL trial...
06/23/2023
Oncology
News
Olverembatinib Well-Tolerated in Adults With TKI-Resistant Chronic Myeloid Leukemia
10/17/2022
Olverembatinib, a novel tyrosine kinase inhibitor (TKI), was well tolerated and demonstrated significant anti-leukemic activity in adults with TKI-resistant CML-CP and CML-AP, especially those with the T315I mutation, according to results...
Olverembatinib, a novel tyrosine kinase inhibitor (TKI), was well tolerated and demonstrated significant anti-leukemic activity in adults with TKI-resistant CML-CP and CML-AP, especially those with the T315I mutation, according to results...
Olverembatinib, a novel tyrosine...
10/17/2022
Oncology
News
FDA Approves Asciminib for Ph+ CML
11/01/2021
The FDA granted accelerated approval to asciminib for the use in the treatment of patients with Ph+ CML in CP with or without the T315I mutation who were previously treated with 2 or more TKIs.
The FDA granted accelerated approval to asciminib for the use in the treatment of patients with Ph+ CML in CP with or without the T315I mutation who were previously treated with 2 or more TKIs.
The FDA granted accelerated...
11/01/2021
Oncology
News
Generic Version Yields Similar Efficacy, Safety to Imatinib in CML-CP
10/08/2020
Results from a prospective study in India show that the generic version of imatinib yields similar efficacy and safety, with lower cost, in patients with CML-CP.
Results from a prospective study in India show that the generic version of imatinib yields similar efficacy and safety, with lower cost, in patients with CML-CP.
Results from a prospective study...
10/08/2020
Oncology
News
Major BCR-ABL1 Transcript Type Linked to Better Imatinib Response in CML
09/29/2020
Study findings suggest that b3a2 transcript may be tied to better responses to imatinib therapy in patients with CML.
Study findings suggest that b3a2 transcript may be tied to better responses to imatinib therapy in patients with CML.
Study findings suggest that b3a2...
09/29/2020
Oncology
News
Michael Mauro, MD, Talks ELN/NCCN Recommendations for Patients With CML
07/18/2020
At the virtual Great Debates & Updates in Hematologic Malignancies, Michael Mauro, MD, presented on practical approaches for monitoring patients with CML as per NCCN and ELN recommendations.
At the virtual Great Debates & Updates in Hematologic Malignancies, Michael Mauro, MD, presented on practical approaches for monitoring patients with CML as per NCCN and ELN recommendations.
At the virtual Great Debates &...
07/18/2020
Oncology
News
Low-Dose TKIs Before Therapy Cessation Leave Treatment-Free Remission Rates Unscathed in CML
06/15/2020
Retrospective study findings demonstrated that, in patients with CML, administration of low-dose TKIs before TKI cessation does not impair treatment‐free remission.
Retrospective study findings demonstrated that, in patients with CML, administration of low-dose TKIs before TKI cessation does not impair treatment‐free remission.
Retrospective study findings...
06/15/2020
Oncology
News
NGS Preferable for Detecting Certain Mutations in Patients With CML
05/14/2020
Study findings support using NGS to illustrate BCR-ABL1 mutation status in patients with CML who do not respond or have warning responses to TKI therapy.
Study findings support using NGS to illustrate BCR-ABL1 mutation status in patients with CML who do not respond or have warning responses to TKI therapy.
Study findings support using NGS...
05/14/2020
Oncology

Interactive Features

Test Your Knowledge
Quiz: Which of the Following is Not a Standard of Care Treatment Option for CML?
09/10/2021
Which of the following is not a current standard of care option for the treatment of patients with CML?
Which of the following is not a current standard of care option for the treatment of patients with CML?
Which of the following is not a...
09/10/2021
Oncology
Test Your Knowledge
Quiz: Is the Major BCR-ABL1 Transcript Type Linked to Better Imatinib Response in CML?
04/20/2021
Study findings reported by researchers in Algeria suggest that b3a2 transcript may be tied to ____ (better/worse) responses to imatinib therapy in patients with chronic myeloid leukemia.
Study findings reported by researchers in Algeria suggest that b3a2 transcript may be tied to ____ (better/worse) responses to imatinib therapy in patients with chronic myeloid leukemia.
Study findings reported by...
04/20/2021
Oncology
Test Your Knowledge
Quiz: Which Treatment is Considered Gold Standard for CML-CP?
03/16/2021
According to experts, which of the following therapy options is considered the gold standard for frontline treatment of newly diagnosed chronic myeloid leukemia in chronic-phase?
According to experts, which of the following therapy options is considered the gold standard for frontline treatment of newly diagnosed chronic myeloid leukemia in chronic-phase?
According to experts, which of...
03/16/2021
Oncology
Test Your Knowledge
Quiz: Have TKIs Improved the CML Alternative Treatment Landscape?
02/17/2021
Prior to experts utilizing tyrosine kinase inhibitors as treatment for chronic myeloid leukemia, a stem cell transplant was required.
Prior to experts utilizing tyrosine kinase inhibitors as treatment for chronic myeloid leukemia, a stem cell transplant was required.
Prior to experts utilizing...
02/17/2021
Oncology
Test Your Knowledge
Quiz: What Was the Outcome of the ASCEMBL Trial?
12/23/2020
True of False: The ASCEMBL data concludes that, with ABL-specific inhibition, asciminib has a reduced rate of side effects that lead to discontinuation or dose adjustment compared to the TKI drug bosutinib, while improving the response rate...
True of False: The ASCEMBL data concludes that, with ABL-specific inhibition, asciminib has a reduced rate of side effects that lead to discontinuation or dose adjustment compared to the TKI drug bosutinib, while improving the response rate...
True of False: The ASCEMBL data...
12/23/2020
Oncology
Test Your Knowledge
Quiz: Is Imatinib Considered Gold Standard Frontline Treatment for CML-CP?
11/25/2020
True or False: Imatinib is considered the gold standard for frontline treatment of newly diagnosed chronic myeloid leukemia in chronic-phase.
True or False: Imatinib is considered the gold standard for frontline treatment of newly diagnosed chronic myeloid leukemia in chronic-phase.
True or False: Imatinib is...
11/25/2020
Oncology
Test Your Knowledge
Quiz: Is Additional FISH Testing Info in CML Overlooked?
10/28/2020
True or False: Although FISH testing has been applied to provide definitive information in chronic myeloid leukemia, additional information provided by FISH testing, such as atypical signal patterns that indicate for complicated chromosomal...
True or False: Although FISH testing has been applied to provide definitive information in chronic myeloid leukemia, additional information provided by FISH testing, such as atypical signal patterns that indicate for complicated chromosomal...
True or False: Although FISH...
10/28/2020
Oncology
Test Your Knowledge
Quiz: Which Clinical Trial Approved the Use of Imatinib for CML?
09/25/2020
Which clinical trial displayed results that were in favor of imatinib, both in terms of efficacy and tolerability, for chronic myeloid leukemia?
Which clinical trial displayed results that were in favor of imatinib, both in terms of efficacy and tolerability, for chronic myeloid leukemia?
Which clinical trial displayed...
09/25/2020
Oncology
Test Your Knowledge
Quiz: Do Low-Dose TKIs Prior to Therapy Cessation Impair CML Remission Rates?
08/19/2020
True or False: The administration of low-dose TKIs before TKI cessation impairs treatment‐free remission in patients with CML.
True or False: The administration of low-dose TKIs before TKI cessation impairs treatment‐free remission in patients with CML.
True or False: The...
08/19/2020
Oncology
Test Your Knowledge
Quiz: Switching From Imatinib to Dasatinib in Chronic-Phase CML
07/28/2020
True or False: Switching from imatinib to dasatinib, in cases of suboptimal response, may offer clinical benefit in patients with CML.
True or False: Switching from imatinib to dasatinib, in cases of suboptimal response, may offer clinical benefit in patients with CML.
True or False: Switching from...
07/28/2020
Oncology

Recent News

FDA Approval
FDA Grants Accelerated Approval to Frontline Asciminib for Patients With Ph+ Chronic Myeloid Leukemia
10/29/2024
The FDA granted accelerated approval to asciminib for patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
The FDA granted accelerated approval to asciminib for patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
The FDA granted accelerated...
10/29/2024
Oncology
News
Nilotinib, Dasatinib, or Flumatinib vs Imatinib as Frontline Therapy for Patients With Chronic-Phase Chronic Myeloid Leukemia
03/22/2024

Amber Denham

Amber Denham
According to a real-world, retrospective study, nilotinib, dasatinib, or flumatinib therapy each showed comparable efficacy, higher therapy responses and higher failure-free survival rates than imatinib among newly diagnosed patients with...
According to a real-world, retrospective study, nilotinib, dasatinib, or flumatinib therapy each showed comparable efficacy, higher therapy responses and higher failure-free survival rates than imatinib among newly diagnosed patients with...
According to a real-world,...
03/22/2024
Oncology
News
Asciminib Demonstrated Superior Efficacy and Safety Compared to Bosutinib Among Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
06/23/2023
Results from the ASCEMBL trial indicated that asciminib, a BCR::ABL1 inhibitor, demonstrated superior efficacy and safety compared to bosutinib among patients with Philadelphia chromosome-positive chronic myeloid leukemia.
Results from the ASCEMBL trial indicated that asciminib, a BCR::ABL1 inhibitor, demonstrated superior efficacy and safety compared to bosutinib among patients with Philadelphia chromosome-positive chronic myeloid leukemia.
Results from the ASCEMBL trial...
06/23/2023
Oncology
News
Olverembatinib Well-Tolerated in Adults With TKI-Resistant Chronic Myeloid Leukemia
10/17/2022
Olverembatinib, a novel tyrosine kinase inhibitor (TKI), was well tolerated and demonstrated significant anti-leukemic activity in adults with TKI-resistant CML-CP and CML-AP, especially those with the T315I mutation, according to results...
Olverembatinib, a novel tyrosine kinase inhibitor (TKI), was well tolerated and demonstrated significant anti-leukemic activity in adults with TKI-resistant CML-CP and CML-AP, especially those with the T315I mutation, according to results...
Olverembatinib, a novel tyrosine...
10/17/2022
Oncology
News
FDA Approves Asciminib for Ph+ CML
11/01/2021
The FDA granted accelerated approval to asciminib for the use in the treatment of patients with Ph+ CML in CP with or without the T315I mutation who were previously treated with 2 or more TKIs.
The FDA granted accelerated approval to asciminib for the use in the treatment of patients with Ph+ CML in CP with or without the T315I mutation who were previously treated with 2 or more TKIs.
The FDA granted accelerated...
11/01/2021
Oncology
News
Generic Version Yields Similar Efficacy, Safety to Imatinib in CML-CP
10/08/2020
Results from a prospective study in India show that the generic version of imatinib yields similar efficacy and safety, with lower cost, in patients with CML-CP.
Results from a prospective study in India show that the generic version of imatinib yields similar efficacy and safety, with lower cost, in patients with CML-CP.
Results from a prospective study...
10/08/2020
Oncology
News
Major BCR-ABL1 Transcript Type Linked to Better Imatinib Response in CML
09/29/2020
Study findings suggest that b3a2 transcript may be tied to better responses to imatinib therapy in patients with CML.
Study findings suggest that b3a2 transcript may be tied to better responses to imatinib therapy in patients with CML.
Study findings suggest that b3a2...
09/29/2020
Oncology
News
Michael Mauro, MD, Talks ELN/NCCN Recommendations for Patients With CML
07/18/2020
At the virtual Great Debates & Updates in Hematologic Malignancies, Michael Mauro, MD, presented on practical approaches for monitoring patients with CML as per NCCN and ELN recommendations.
At the virtual Great Debates & Updates in Hematologic Malignancies, Michael Mauro, MD, presented on practical approaches for monitoring patients with CML as per NCCN and ELN recommendations.
At the virtual Great Debates &...
07/18/2020
Oncology
News
Low-Dose TKIs Before Therapy Cessation Leave Treatment-Free Remission Rates Unscathed in CML
06/15/2020
Retrospective study findings demonstrated that, in patients with CML, administration of low-dose TKIs before TKI cessation does not impair treatment‐free remission.
Retrospective study findings demonstrated that, in patients with CML, administration of low-dose TKIs before TKI cessation does not impair treatment‐free remission.
Retrospective study findings...
06/15/2020
Oncology
News
NGS Preferable for Detecting Certain Mutations in Patients With CML
05/14/2020
Study findings support using NGS to illustrate BCR-ABL1 mutation status in patients with CML who do not respond or have warning responses to TKI therapy.
Study findings support using NGS to illustrate BCR-ABL1 mutation status in patients with CML who do not respond or have warning responses to TKI therapy.
Study findings support using NGS...
05/14/2020
Oncology
News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use